
For mTatt, this program will be invaluable in validating the market for our microneedle tattoo technology. It allows us to engage directly with potential users and stakeholders, gather feedback on needs and preferences, identify real-world applications, and refine our business model. This process ensures that our innovation is not only scientifically groundbreaking but also meets real market needs.
Participating in Lab2Market Validate brings us closer to turning our vision of minimally invasive, real-time physiological monitoring into a solution that truly serves the health and wellness of patients.
Disclaimer: The mTatt patch is currently under development, has not been approved by regulatory authorities, and is not yet available for sale.
Contact: Samuel Babity — Co-Founder and CEO
Sources: mTatt